Bharat Parenterals Ltd

Bharat Parenterals Ltd share price declined by 0.45% to Rs 1910.15 after the company's net profit tanked by 432.02% to Rs 11.82 crore, while revenue from operations increased sharply by 45.38% to Rs 136.28 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, gaining 4.44%. It has improved by 5.74% over last one week and ticked higher by 0.60% in last one month while the market capitalization of Bharat Parenterals Ltd has gained 14.88% and 29.95% in the same period respectively. Profit before tax (PBT) of Bharat Parenterals Ltd stood at Rs 14.0 crore in Q3 FY26, crashing by 291.52% year-on-year, and nosediving by 1039.60% quarter-on-quarter. EBITDA came in at Rs 21 crore, tanking 876.38% YoY and expanding by 183.18% sequentially. Total expenses jumped by 29.63% to Rs 121.71 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 60.27 crore, jumping 48.81% YoY, while employee benefits expense was at Rs 21.43 crore, soaring 13.75% YoY. For the TTM ended FY26, revenue from operations inched higher 1.48% to Rs 345.43 crore, while net profit witnessed a sharp fall of 37.48% to Rs 27.31 crore, compared to previous TTM. EBITDA saw a sharp decline of 1099% to Rs 6.28 crore, and PBT collapsed by 36.91% to Rs 21.42 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 38.36 crore in FY26, as against Rs 27.25 crore in FY25. Bharat Parenterals Ltd rallied 57.88% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 12.76% during the same period.

Bharat Parenterals Ltd share price inched up 1.83% to Rs 1918.7 after the company's net profit plunged by 432.02% to Rs 11.82 crore, while revenue from operations gained significantly 45.38% to Rs 136.28 crore in Q3FY26 over Q2FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, easing 4.28%. It has improved by 3.87% over last one week and moved up slightly by 0.06% in last one month while the market capitalization of Bharat Parenterals Ltd has marginally improved by 7.25% and 30.53% in the same period respectively. Profit before tax (PBT) of Bharat Parenterals Ltd stood at Rs 14.0 crore in Q3 FY26, crashing by 291.52% year-on-year, and plunging by 1039.60% quarter-on-quarter. EBITDA came in at Rs 21 crore, tumbling by 876.38% YoY and expanding by 183.18% sequentially. Total expenses soared by 29.63% to Rs 121.71 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 60.27 crore, witnessing a sharp rise of 48.81% YoY, while employee benefits expense was at Rs 21.43 crore, jumping 13.75% YoY. For the TTM ended FY26, revenue from operations grew marginally by 1.48% to Rs 345.43 crore, while net profit tanked by 37.48% to Rs 27.31 crore, compared to previous TTM. EBITDA saw a sharp decline of 1099% to Rs 6.28 crore, and PBT collapsed by 36.91% to Rs 21.42 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 38.36 crore in FY26, as against Rs 27.25 crore in FY25. Bharat Parenterals Ltd surged by 54.12% in last one year, significantly outperforming the benchmark BSE Sensex which has slipped by 13.45% during the same period.

Bharat Parenterals Limited has issued a corrigendum to the notice of its Extraordinary General Meeting (EGM) scheduled for October 23, 2026, following a direction from the BSE Limited. The corrigendum, pertaining to Item No. 1 concerning a proposed preferential issue of equity shares, includes additional disclosures regarding the appointment of Crisil Ratings Limited as a monitoring agency, as required by Securities and Exchange Board of India (SEBI) regulations due to the issue size exceeding Rs 100 crore.

Bharat Parenterals Limited, in compliance with Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, confirmed that securities received from depository participants for dematerialization during the quarter ended September 30, 2026, were accepted or rejected by Adroit Corporate Services Private Limited, the company’s registrar and share transfer agent, and that the securities have been listed on stock exchanges.

Bharat Parenterals Limited informed the BSE Limited that the trading window for dealing in the company's equity shares will be closed from October 1, 2026, until 48 hours after the declaration of unaudited financial results (standalone and consolidated) for the quarter and half year ended September 30, 2026.

Bharat Parenterals Limited will hold a board meeting on Tuesday, September 29, 2026, to consider and evaluate a proposal for the issuance of equity shares or other eligible securities via a preferential issue, according to a regulatory filing with the BSE Limited. The company’s trading window will be closed from September 24, 2026, until 48 hours after the conclusion of the meeting, as per its code of conduct for regulating trading by designated persons.

Bharat Parenterals Limited has set Saturday, September 12, 2026, as the record date for determining entitlement to receive a dividend for the financial year 2025-26, subject to approval by members at the annual general meeting scheduled for 2026.

Bharat Parenterals Ltd share price slipped 1.57% to Rs 1441.7 after the company's net profit plunged by 56.37% to Rs 3.56 crore, while revenue from operations eased by 5.90% to Rs 93.74 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 24.82 lakh crore, gaining 4.98%. It has inched up 0.66% over last one week and heading higher by 11.72% in last one month while the market capitalization of Bharat Parenterals Ltd has softened by 2.27% and 20.64% in the same period respectively. Profit before tax (PBT) of Bharat Parenterals Ltd stood at Rs 1.49 crore in Q2 FY26, plunging by 158.43% year-on-year, and tumbling by 82.20% quarter-on-quarter. EBITDA came in at Rs 7 crore, nosediving by 41.54% YoY and tanking 279.04% sequentially. Total expenses contracted by 13.69% to Rs 93.89 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 40.5 crore, registering a fall of 21.13% YoY, while employee benefits expense was at Rs 18.84 crore, inching up 2.06% YoY. For the TTM ended FY26, revenue from operations surged 30.30% to Rs 340.38 crore, while net profit tanked by 515.60% to Rs 43.68 crore, compared to previous TTM. EBITDA soared by 4770% to Rs 8.92 crore, and PBT collapsed by 281.36% to Rs 33.95 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 27.25 crore in FY26, as against Rs 4.71 crore in FY25. Bharat Parenterals Ltd declined by 3% in last one year, performing in line with the benchmark BSE Sensex which has eased by 3.20% during the same period.

Bharat Parenterals Limited informed the BSE Limited that its board of directors approved the re-appointment of Mr. Hemang Shah as an Executive Director for a term of 5 consecutive years, effective July 2, 2026, to July 1, 2031, subject to shareholder approval at the upcoming Annual General Meeting.

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 5 August 2026.